# Reduced Anticoagulation Targets in ECLS (RATE)

> **NCT04536272** · PHASE3 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 330 (actual)

## Conditions studied

- Heart Failure
- Respiratory Failure
- Extracorporeal Membrane Oxygenation
- Bleeding
- Thrombosis

## Interventions

- **DRUG:** Heparin
- **DRUG:** LMWH

## Key facts

- **NCT ID:** NCT04536272
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2025-03-07
- **Final completion:** 2025-03-07
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536272, "Reduced Anticoagulation Targets in ECLS (RATE)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04536272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*